ALLO Allogene Therapeutics Inc
2,839
$2.61
$0.16
(5.78%)
| Watchers | 2,839 |
| 52-Wk Low | $2.23 |
| 52-Wk High | $6.41 |
| Market Cap | $473.26M |
| Volume | 1.65M |
| 52-Wk High | $6.41 |
| 52-Wk Low | $2.23 |
Breaking Down Allogene Therapeutics: 5 Analysts Share Their ViewsBenzinga • 5 days ago
Latest Ratings for ALLO
DateFirmActionFromTo Mar 2022Goldman SachsMaintainsNeutral Dec 2021RBC CapitalMaintainsOutperform Oct 2021JMP SecuritiesMaintainsMarket Outperform
View More Analyst...
Share to Feed
read more...
This price move could indicate a change in the trend, and may be a sell signal for investors...
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside...
Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Research analysts at Zacks Research issued their FY2026 earnings per share (EPS) estimates for Allogene Therapeutics in a research report...
This is a signal that ALLO's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
This price move could indicate a change in the trend, and may be a sell signal for investors...
HC Wainwright reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright...
Allogene Therapeutics (NASDAQ:ALLO Get Free Report)s stock had its buy rating reissued by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...